 |
|
|
| |
A Phase 2b Trial Comparing 24 to 48 Weeks Treatment with Tegobuvir (GS-9190)/PEG/RBV
to 48 Weeks Treatment with PEG/RBV for Chronic Genotype 1 HCV Infection
|
| |
| |
Reported by Jules Levin EASL 2011 Berlin March 31-Apr 2
E Lawitz,1 I Jacobson,2 E Godofsky,3 G Foster,4 R Flisiak,5 M Bennett,6 M Ryan,7 JM Pawlotsky,8 Hinkle,9 J Simpson,9 J McHutchison,9 D Oldach,9 and M DeMicco10
1Alamo Medical Research, San Antonio, TX, USA; 2Weill Medical College of Cornell University, NY, NY, USA; 3Bach and Godofsky Infectious Diseases, Sarasota, FL, USA; 4Barts and The London Hopsital, London, UK;
5Klinika Chorob Zakaznych I Hepatologii, Bialystok, Poland; 6Medical Associates Research Group, San Diego, CA, USA; 7Digestive and Liver Disease Specialists, Norfolk, VA, USA; 8Henri Mondor Hospital, Paris, France;
9Gilead Sciences, Inc., Foster City, CA, USA; 10Advanced Clinical Research Institute, Anaheim, CA, USA
|
| |
|
|
|
|
|
